Mumbai (Maharashtra) [India], February 15 (ANI/PR Newswire): Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Designation' for its blood test to detect early-stage prostate cancer. This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA. Late last year, the company's breast cancer detection test became the first such test to receive the designation.
\
\
